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Activated PI3 kinase delta syndrome (APDS) is a primary immunodeficiency caused by 
dominant mutations that increase activity of phosphoinositide-3-kinase δ (PI3Kδ). APDS 
can be caused by mutations in the PIK3CD gene that encodes PI3Kδ catalytic subunit 
p110δ (APDS1) or mutations in the PIK3R1 gene that encodes regulatory subunit p85α 
(APDS2). APDS research advanced rapidly after the initial discovery in 2013. More 
than 200 APDS patients have been identified around the world. Multiple novel APDS 
mutations were reported and molecular mechanisms leading to PI3Kδ activation have 
been elucidated. The finding of APDS significantly increased our understanding of the 
role of PI3Kδ in the human immune system. Perhaps most importantly, discovery of 
the molecular basis of this primary immunodeficiency suggested that APDS patients, 
who previously received only non-specific therapy, could be treated by a novel class of 
drugs that inhibits PI3Kδ activity. This led to the ongoing clinical trials of selective PI3Kδ 
inhibitors in APDS patients. Overall, the APDS story provides an excellent example of 
translational research, beginning with patients who had an unknown disease cause and 
leading to a novel specific knowledge-based treatment.
Keywords: activated Pi3 kinase delta syndrome, primary immunodeficiency, phosphoinositide-3-kinase δ, 
mutation, inhibitor
inTRODUCTiOn
Primary immunodeficiencies (PIDs) are a group of disorders that cause immune dysfunction and 
manifest with increased susceptibility to infections. Many PIDs are monogenic diseases. To date, 
mutations in more than 300 genes have been shown to cause various PIDs (1). Activated PI3 kinase 
delta syndrome (APDS) is a PID that results from gain-of-function mutations in genes encoding the 
phosphoinositide-3-kinase δ (PI3Kδ). This review will focus on the APDS mutations, phenotypes of 
the disease, and current therapeutic approaches.
Phosphoinositide-3-kinase δ is a class IA lipid kinase that phosphorylates phosphatidylinosi-
tol-4,5-bisphosphate [PtdIns(4,5)P2 or PIP2] to produce phosphatidylinositol-3,4,5-trisphosphate 
[PtdIns(3,4,5)P3 or PIP3]. There are three class IA PI3Ks in mammalian cells: α, β, and δ. Each 
class IA PI3K is composed of a catalytic subunit: p110α, p110β, or p110δ (encoded by genes 
PIK3CA, PIK3CB, and PIK3CD, respectively), and one of the five regulatory subunits: p85α, p55α, 
p50α (all encoded by different transcripts of the PIK3R1 gene), p85β (encoded by the PIK3R2 
gene), or p55γ (encoded by the PIK3R3 gene). The regulatory subunit stabilizes the catalytic 
subunit to prevent its proteasomal degradation, inhibits activity of the catalytic subunit, and 
recruits it to the plasma membrane (2). Catalytic subunits p110α and p110β are broadly expressed, 
while p110δ is mainly expressed in cells of the hematopoietic system, primarily lymphocytes and 
myeloid cells (3). In immune cells, PI3Kδ is activated downstream of cytokine receptors, toll-like 
AB
FiGURe 1 | (A) Domain structure of the p110δ and p85α proteins and positions of mutations. ABD, adaptor-binding domain; RBD, Ras-binding domain; BH, 
breakpoint cluster region homology domain; P, proline-rich regions. (B) Activated PI3 kinase delta syndrome mutations in the PIK3CD (5, 6, 9–15, 19) and PIK3R1 
(7, 8, 14, 20) genes. 1—NM_005026; 2—NM_181523 (RefSeq); 3—O00329; 4—P27986 (UniProt).
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receptors, B-cell and T-cell receptors, and Ras superfamily of 
small GTPases (4). PIP3 produced by PI3Ks activates kinases 
PDK1 and AKT, leading to the activation of mTOR complex 
1 and inhibition of FOXO family of transcription factors. In 
lymphocytes, PIP3 activates kinases BTK and ITK that mediate 
activation of phospholipase Cγ and other proteins (3). PIP3 is 
dephosphorylated to PIP2 by a phosphatase PTEN.
APDS MUTATiOnS
In 2013, two groups, one in Cambridge (UK) and the other in 
Bethesda (USA), used whole-exome-sequencing analysis of PID 
patients with unknown etiology and reported a novel PID caused 
by rare heterozygous germline gain-of-function mutations in the 
PIK3CD gene (5, 6). The mutations led to the increased PI3Kδ 
activity and the disease was called APDS (5) or p110δ-activating 
mutation causing senescent T  cell, lymphadenopathy, and 
immunodeficiency (PASLI) (6) (OMIM #615513). Subsequently, 
rare heterozygous germline mutations in the PIK3R1 gene were 
described that also resulted in an increased PI3Kδ activity and 
immune deficiency, phenocopying patients with the PIK3CD 
mutations. This disorder has been termed APDS2 or PASLI-R1 
(7, 8) (OMIM #616005). Now, a PID caused by activating muta-
tions in the PIK3CD gene is referred to as APDS1 and both 
diseases together are known as APDS.
Since the initial publications, 10 activating missense mutations 
have been reported in the PIK3CD gene resulting in APDS1 (5, 6, 
9–15) (Figure 1). The E1021K variant in the C-lobe of the p110δ 
kinase domain is by far the most frequently reported APDS 
mutation. In the p110δ protein, E1021K is positioned similar to 
the somatic mutation H1047R of another PI3K isoform, p110α. 
Both E1021K and H1047R increase PI3K activity by enhancing 
association of the catalytic subunits with membranes and facili-
tating more effective phosphorylation of PIP2 (5, 16–18). The 
R929C mutation in the C-lobe of the p110δ kinase domain may 
also act in a similar manner (14). Other p110δ mutations located 
in the C2 domain (N334K, C416R) and the helical domain 
(E525K) likely interfere with inhibitory contacts between p110δ 
and p85α (18). Interestingly, activating somatic mutations of the 
homologous amino-acid residues of p110α (N345, C420, and 
E545) have been also found in tumors. The recently identified 
E81K and G124D mutations in the adapter-binding domain and 
the linker between the adapter-binding and the Ras-binding 
domains may affect the orientation of the adapter-binding 
domain and hence interaction between p110δ and p85α (11).
Several mutations causing APDS2 were identified in the 
PIK3R1 gene (Figure 1). These include one missense mutation 
and seven mutations affecting the splice sites of exon 11 (coding 
exon 10), one affecting the splice acceptor site, and six affecting 
the splice donor site. All splice site mutations lead to the skipping 
of exon 11 and an in-frame deletion of 42 amino-acid residues 
in positions 434–475 within the inter-SH2 coiled-coil domain 
of p85α. The additional N564K variant in p85α is also found in 
the inter-SH2 domain (14). The inter-SH2 domain of p85α is 
TABle 1 | Characteristic clinical and immunological features of activated PI3 
kinase delta syndrome (APDS).
Manifestations APDS1 (22) APDS2 (20)
Recurrent respiratory tract infections 96% 100%
Pneumonia 85% 71%
Bronchiectasis 60% 18%
Herpesvirus infections 49% 31%
Lymphadenopathy 64% 75%
Splenomegaly 58% 43%
Autoimmune or autoinflammatory disease 34% 17%
Neurodevelopmental delay 19% 31%
Lymphoma 13% 25%
Increased IgM 76% 58%
Increased transitional B cellsa 75% 93%
aIf data were available and B cells were sufficient for analysis.
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known to inhibit the catalytic p110 subunit by interacting with 
its C2 domain (2). Interestingly, the APDS2 mutations in p85α 
lead to the disease that phenocopy APDS1, despite that p85α is 
ubiquitously expressed and interacts not only with p110δ but 
also with p110α and p110β. However, it has been demonstrated 
that the 42 amino-acid deletion in p85α effectively disrupts 
inhibitory interactions between p85α and p110δ, leading to a 
strong basal activation of PI3Kδ, while it only weakly increases 
PI3Kα activity (18). This differential effect explains why the 
impact of this mutation is largely restricted to the immune 
system.
Mutations that cause APDS have been found in patients 
from different countries around the world. So far, more than 
200 APDS patients carrying activating mutations in the PIK3CD 
and PIK3R1 genes have been identified. None of these variants 
were found in large cohorts of healthy subjects, e.g., they are 
absent from the largest human exome and whole-genome 
database gnomAD that includes more than 138,000 subjects 
(21). In several families, APDS mutations were shown to appear 
de novo among children, while being absent in their parents (5, 
6, 10, 20), and long-range haplotype analysis in families with the 
E1021K mutation showed no founder effect (5). These findings 
indicate that APDS mutations appear recurrently in human 
populations. It is possible that activation of PI3Kδ provides 
selective advantages to cells during gametogenesis. Current data 
show that APDS mutations have high penetrance, e.g., out of the 
53 subjects from 30 APDS1 families only one adult carrier of the 
E1021K mutation had no reported health issues (22). The true 
prevalence of APDS is not known. In the original study, hetero-
geneous cohorts comprising 184 PID patients were screened for 
the E1021K mutation and 17 APDS patients from seven unrelated 
families were identified (5). However, these cohorts included 
multiple patients with hyper-IgM syndrome and, therefore, 
were enriched for APDS mutations. Another study screened 669 
patients with undefined PIDs for the N334K, C416R, E525K, 
and E1021K mutations in PIK3CD and the PIK3R1 splice site 
mutations and found only PIK3CD mutations in three siblings 
diagnosed with common variable immune deficiency (CVID) 
and two sporadic cases with combined immunodeficiency (23). 
Thus, prevalence of APDS may vary considerably between dif-
ferent PID cohorts.
APDS PHenOTYPeS
Two comprehensive studies of APDS cohorts have been carried 
out recently and characterized its clinical and immunological 
manifestations (Table 1). One study examined the phenotypes 
of 53 patients with APDS1 (50 subjects with E1021K and 3 
subjects E525K mutations) (22). The other studied 36 patients 
with APDS2 (20). Almost all APDS1 and APDS2 patients suf-
fered from recurrent respiratory infections caused by bacterial 
pathogens, mainly Streptococcus pneumoniae and Haemophilus 
influenzae. Bronchiectasis was a common complication of lung 
infections affecting up to 60% of APDS1 patients. Interestingly, 
the majority of bronchiectasis patients had normal IgG levels 
and diagnosing PID in such subjects may not have been 
straightforward. Therefore, screening bronchiectasis patients 
without a clear PID for APDS mutations can reveal unrecog-
nized APDS cases. Severe, persistent, or recurrent herpes virus 
infections, including EBV, CMV, HSV, and VZV infections, 
were found in 49% APDS1 and 31% APDS2 patients and were 
associated with lymphadenopathy. Immunologically, increased 
frequency of transitional B cells was often observed in APDS 
patients (Table  1). Many patients also had increased serum 
IgM levels and, therefore, some of the patients previous were 
diagnosed with hyper-IgM syndrome (5). Approximately one 
third of APDS1 patients and 17% of APDS2 patients had auto-
immune or autoinflammatory manifestations. High incidence 
of lymphomas was also recorded in APDS patients (20, 22, 24). 
Unexpectedly, neurodevelopmental delay was found to be 
a relatively frequent manifestation in both APDS cohorts 
(Table 1), which may suggest an important role of PI3Kδ in the 
development of central nervous system that was not recognized 
previously.
Thus, APDS manifests as a PID with a high rate of recurrent 
respiratory tract infections, often leading to bronchiectasis, 
herpes virus infections, lymphadenopathy, splenomegaly, 
increased risk of lymphomas, frequent autoimmune manifes-
tations, and, occasionally, developmental delay. In addition, 
APDS2 patients had a high frequency of growth retardation 
(45%), a feature that was not found in APDS1 patients. This 
difference may reflect impaired interactions of p85α with 
p110α and p110β catalytic subunits. Of note, a number of 
other dominant germline mutations, which reside within the 
nSH2 and iSH2 domains of p85α and reduce PI3K signaling, 
are known to cause the SHORT syndrome that includes short 
stature, hyperextensibility of joints, hernia, ocular depression, 
Rieger anomaly, and teething delay (25–28) (OMIM #269880). 
A single patient with a homozygous loss-of-function mutation 
in the PIK3R1 gene was described that resulted in the absent 
p85α and reduced expression of p110δ. The patient had B 
lymphopenia and hypogammaglobulinemia and suffered from 
recurrent Campylobacter bacteremia and inflammatory bowel 
disease (29) (OMIM #615214). Also, a patient with biallelic loss-
of-function mutations in the PIK3CD gene and reduced p110δ 
expression was reported to have B lymphopenia and hypogam-
maglobulinemia, sinopulmonary infections, septic arthritis, 
inflammatory bowel disease, and autoimmune hepatitis (30). 
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Therefore, although p110δ deficiency also leads to a PID, its 
phenotype is different from APDS.
THeRAPieS FOR APDS PATienTS––
PReCiSiOn MeDiCine FOR A RARe 
DiSeASe
Treatment regimes for APDS patients include antibiotic prophy-
laxis and immunoglobulin replacement therapy. Hematopoietic 
stem cell transplantation (HSCT) has been successful in several 
APDS patients and can be a treatment option, especially in young 
patients (20, 22). Immunosuppressive therapies aimed at reduc-
ing lymphoproliferation have included treatment with rituximab 
(anti-CD20 monoclonal antibody) and rapamycin to target the 
activation of the mTOR pathway. Treatment with rapamycin led 
to the improvement of immunological markers and a reduction in 
splenomegaly and lymphadenopathy (6). Nevertheless, the discov-
ery of the APDS etiology and the causative role of mutations that 
activate PI3Kδ opened an opportunity for a novel specific treat-
ment using selective PI3Kδ inhibitors. This class of drugs has been 
developed for cancer treatment (31), as well as inflammatory disor-
ders, such as rheumatoid arthritis, asthma, and chronic obstructive 
pulmonary disease (COPD) (32–34). One of the PI3Kδ inhibitors, 
idelalisib, has been approved for treatment of chronic lymphocytic 
leukemia and non-Hodgkin lymphoma (35, 36). Idelalisib (previ-
ously known as GS-1101) reduced the catalytic activity of mutant 
PI3Kδ as efficiently as the activity of the wild type PI3Kδ (5, 18). 
PI3Kδ inhibitors also normalized PI3Kδ hyperactivation in cells 
of APDS patients in vitro (5–8, 37). These results opened way for 
clinical trials of PI3Kδ inhibitors in APDS patients.
Two phase-II clinical trials are currently ongoing to study the 
safety, pharmacokinetics, pharmacodynamics, and efficacy of 
PI3Kδ inhibitors in APDS patients. Clinical trial NCT02435173 
sponsored by Novartis uses an oral PI3Kδ inhibitor leniolisib 
(CDZ173) (38), while clinical trial NCT02593539 sponsored by 
GSK uses an inhaled PI3Kδ inhibitor nemiralisib (GSK2269557) 
(39) that had been originally developed for treatment of COPD 
(34). Recently, the clinical trial NCT02435173 has reported effi-
cacy data from six APDS patients (37). The patients were part of 
a 12-week within subject dose-escalation study of oral leniolisib, 
administered twice daily. Leniolisib was well tolerated and the 
study reported normalization of circulating transitional and naïve 
B cells, reduction in senescent T cells, decrease in the elevated 
serum IgM levels, and inflammatory markers. After 12  weeks 
of treatment, lymph node and spleen sizes reduced by 39% and 
40%, respectively (37). Normalization of immunophenotypes 
was most notable in the final 4-week dosing period. The study 
has now proceeded to a long-term treatment arm with patients 
receiving treatment for over 9  months (70-mg leniolisib, twice 
daily) and no significant adverse events have been detected (37). 
These exciting initial findings validate the focused approach to 
target the activated PI3Kδ in APDS patients. It will be of interest 
to see if the oral or inhaled inhibitors under development provide 
specific advantages for the APDS patients. Inhaled PI3Kδ inhibi-
tors will have a different safety profile and may be appropriate 
for patients who are primarily affected by airway infections, 
potentially limiting progression of bronchiectasis.
FUTURe DiReCTiOnS
Whole-exome and whole-genome sequencing of PID patients will 
likely identify novel variants in the PIK3CD and PIK3R1 genes 
and it remains essential to distinguish pathogenic mutations from 
neutral variants. Given that APDS is a rare monogenic disorder 
with high penetrance, variants that cause it are unlikely to be 
found in healthy subjects outside of patients’ families. Therefore, 
excluding variants detected in healthy cohorts, e.g., reported in 
the gnomAD database (21), will help initial screening of potential 
APDS-causing mutations. However, rare variants can still be 
neutral, so it will remain important to demonstrate that a novel 
candidate mutation leads to increased PI3K activity, e.g., by show-
ing increased levels of PIP3 or phosphorylated AKT. The growing 
list of known APDS mutations will facilitate genetic diagnosis 
in future patients. Early diagnosis of APDS will be essential, as 
it will allow early therapy, e.g., HSCT or treatment with PI3Kδ 
inhibitors, which should prevent many APDS complications.
As our understanding of APDS improves, new questions 
emerge. With more APDS patients carrying various mutations being 
identified, it will be interesting to understand if specific mutations 
are associated with disease severity and clinical or immunological 
subphenotypes. The varying degree of disease severity in APDS 
patients raises the question as to whether rare activating muta-
tions in genes encoding PI3Kδ or other proteins that regulate PI3K 
activity may be responsible for causing similar disorders, perhaps 
resembling only some of the APDS manifestations. In support of 
this hypothesis, loss-of-function mutations have been described in 
PTEN resulting in an APDS-like phenotype (10). Larger exome- or 
genome-sequencing studies in patients with diseases that resemble 
aspects of the APDS phenotype will be interesting to explore in 
this regard. These studies may reveal monogenic etiology in some 
of the patients with disorders, such as bronchiectasis. Furthermore, 
it is plausible that combinations of common polymorphisms in 
genes regulating PI3Kδ signaling may lead to its increased activity. 
Such subjects may be predisposed to APDS-like manifestations, 
e.g., bacterial respiratory infections, herpes virus infections, or 
bronchiectasis. Future genetic, biochemical, and immunological 
studies should address these questions.
In conclusion, the story of APDS illustrates how modern 
biomedical approaches led to the discovery of disease etiology 
in a group of uncharacterized patients and then provided a novel 
knowledge-based therapeutic strategy. Promising data emerging 
from the ongoing clinical trials of PI3Kδ inhibitors (37) rises the 
hope that the success of this approach may translate into therapies 
for APDS and, possibly, for APDS-like diseases in future.
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